You are herePharma News
Shiseido Co., Ltd. announces plans to open the Shiseido Cell-Processing and Expansion Center (SPEC) on May 1, 2014. The center, located in the in the Kobe Biomedical Innovation Cluster in Kobe, Japan, will centralize research and development on hair regenerative medicine with an aim toward commercialization.
Indian Council of Medical research (ICMR) releases consensus document for management of esophageal cancer (EC), prepared as an outcome of ICMR Subcommittee on EC.
As per Industry Standard Research’s (ISR) 2014 - CRO Quality Benchmarking Phase II/III Service Providers Report, Quintiles has been named as industry leader that best differentiates itself on service quality for Phase II/III research. They are identified for the second year in a row.
The U.S. Food and Drug Administration approved Tanzeum (albiglutide), manufactured by GlaxoSmithKline, subcutaneous injection to improve glycemic control, along with diet and exercise, in adults with type 2 diabetes.
Team of scientists, from University of Edinburgh, have succeeded in regenerating a living organ for the first time. Living mouse organ is regenerated successfully and transplanted in to a mouse. Regenerated organ closely resembles the juvenile thymus in terms of architecture and gene expression profile.
Ranbaxy saw some good news from the US drug regulator just days before the announcement of its acquisition by Sun Pharmaceutical in a $4-billion deal inclusive of debt.
New studies escalate medical concerns about glioma (a malignant brain tumor) from cell phone use. The BioInitiative Working Group (BWG) noted that evidence for health risk from wireless technology is growing stronger and require immediate action. The Group released a mid-year update covering new science studies from 2012 to 2014.
‘Elbrit Life Sciences’, a new pharmaceutical company based in Mumbai, India, today opened gates for business in India. The company would be serving the South Indian states initially and aims to cover the entire country with time. According to the sources, the company would be targeting cardiac and diabetes product segments in the present year. Elbrit Life Sciences is a part of a global business group based in UK with investments in science, research and education. The group has significantly invested in next generation healthcare such as genetic therapy, molecular biology, DNA mapping and biomarkers. The group also owns world renowned scientific and academic publishing brands.
World Health Organization (WHO) has issued its first guidance for the treatment of hepatitis C which affects an estimated 130 million to 150 million people and results in 3,50,000 to 5,00,000 deaths a year.
The "WHO Guidelines for the screening, care and treatment of persons with Hepatitis C infection" concurs the available effective and safer oral hepatitis medicines, along with the promise of even more new medicines in the next few years.
Combination of Palbociclib with Letrozole significantly prolonging progression of tumor compared with single letrozole in post-menopausal women with estrogen receptor positive. This details resulted from PALOMA-1 study which is a Phase 2 trial designed to assess progression-free survival in post-menopausal women with ER+, HER2- advanced breast cancer receiving palbociclib in combination with letrozole versus letrozole alone.